in 2011, this triple-blinded RCT examined the effects of pantethine 600 (for the first 8 weeks) and 900 (for the second 8 weeks) mg/day in 120 subjects over 16 weeks. Subjects all met criteria for low to moderate CVD risk and completed 4 weeks of the TLC diet at baseline and then initiated treatment with pantetheine or placebo. The researchers found that the pantethine supplementation demonstrated statistically significant reductions (from baseline to week 16) in TC (3%), LDL-C (4%) and apoB (5%). There did not appear to be an obvious dose dependent effect between 600 and 900 mg/day and both doses were well tolerated with only one case of mild diarrhea.
Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608–615